Pfizer’s Champix Faces Patent Hurdle In India As Dr Reddy’s Raise Questions
This article was originally published in The Pink Sheet Daily
Executive Summary
Dr. Reddy’s has been very selective in challenging Indian patents of multinational companies, so lawyers speculate that the undisclosed grounds for the challenge must be very strong.
You may also be interested in...
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)
Pfizer Pushes Champix In India Through Private Hospitals And Clinics As Smoking Epidemic Hits India
MUMBAI - A smoking epidemic that kills nearly a million people in India every year has led Pfizer to get aggressive on collaborating with private sector healthcare units to open 600 smoking cessation clinics in the next two years
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.